Meta-analysis on drugs in people with eating disorders

Calero-Elvira A, Krug I, Davis K, López C, Fernández-Aranda F, Treasure J

European eating disorders review : the journal of the Eating Disorders Association, 2009

Abstract

OBJECTIVE: The aim of this study was to examine whether drug use (DU) is higher in people with eating disorders (EDs) compared to a healthy control group and to perform a meta-analysis on the literature related to DU in people with EDs.

METHOD: We searched electronic databases (Medline, PsycINFO, Web of Science and CINAHL) and reviewed studies published from 1994 to August, 2007, in English, German or Spanish. A total of 16 papers fulfilled the inclusion criteria and were included.

RESULTS: The general meta-analysis revealed a negligible albeit significant effect size (0.119, p < .05). Risk was found to be higher in bulimia nervosa (BN, delta = 0.462, p = < .001), smaller in binge eating disorder (delta = 0.14, p < .05) and non-significant in anorexia nervosa (AN, delta = -.167, p = .070).

CONCLUSIONS: The differential risk observed in patients with BN might be related to differences in temperament or might be the result of reward sensitization.

How strong is the evidence?

Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

• DOI
• PubMed
• Publisher page

Related studies

• The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices Molecular & Cellular Proteomics, 2011
• The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities Proceedings of the National Academy of Sciences, 2000
• In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling British Journal of Pharmacology, 2007
• In silico prediction of splice-altering single nucleotide variants in the human genome Nucleic Acids Research, 2014
• In silico clinical trials: how computer simulation will transform the biomedical industry International Journal of Clinical Trials, 2016
• In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design Nature Communications, 2018

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free